Measures of small and large artery dysfunction have not been investigated in a single cohort for the prediction of cardiovascular (CV) events in patients with nondialysed (ND) chronic kidney disease (CKD). This prospective cohort study aimed to determine whether central pulse wave velocity (cPWV), central pulse pressure (CPP) or microvascular post-occlusive reactive hyperaemia area (PORH HA ) independently predict CV events and mortality in CKD-ND. A total of 94 stage 1-5 CKD-ND (65.3 ± 13.1 years; estimated glomerular filtration rate 35.3 (22.8-49.4) ml min − 1 per 1.73 m 2 ) patients were followed-up for a median of 52 (36-65) months and had baseline cPWV and CPP measured by applanation tonometry and PORH HA by laser Doppler flowmetry. Multiple failure time Cox regression models were used to determine the predictive role of vascular parameters on CV mortality and events. Based on multiple linear regressions, baseline age, diabetes, CV disease, and systolic blood pressure (SBP) were independently related to cPWV (R 2 = 0.3), SBP and PORH HA to CPP (R 2 = 0.45), whereas CPP was the only parameter independently related to PORH HA (R 2 = 0.16, all Po 0.05). During follow-up, 41 CV events occurred (14 CV deaths). In univariate analyses, cPWV (1.07 (1.02-1.13) per m s − 1 ), CPP (1.04 (1.01-1.07) per mm Hg) and lnPORH HA (0.70 (0.58-0.85) per ln(PU × s)) were all related to the outcome. Baseline diabetes (HR 3.07 (1.65-5.68)), lnFGF23 (fibroblast growth factor-23; 1.86 (1.13-3.06) per RU ml 
INTRODUCTION
The risk of cardiovascular (CV) events and all-cause mortality increases with worsening kidney function and it approaches 100-fold in end-stage renal disease (ESRD) compared with the general population. 1 Patients with chronic kidney disease (CKD) are more likely to die of CV disease before they get to ESRD that cannot be fully explained by decreased glomerular filtration (estimated glomerular filtration rate (eGFR)) and traditional risk factors. Thus, CKD-related vascular and metabolic alterations are suspected to explain the additional risk in this population.
Renal anaemia, disturbances in mineral metabolism and systemic inflammation are known to be potential nontraditional CV risk factors [2] [3] [4] and serve as part of the pathophysiological background of accelerated athero-and arteriosclerosis of the large and small arteries in ESRD. Increased central pulse wave velocity (cPWV) and central pulse pressure (CPP) independently predict target organ damage, such as coronary artery disease, acute coronary syndrome, cerebrovascular diseases (stroke or transient ischaemic attack) and peripheral artery disease, at a subclinical stage in ESRD. 5, 6 However, the role of these vascular biomarkers of subclinical organ damage and renal comorbid conditions as risk factors of CV events and death at earlier stages of CKD is uncertain. 7 In fact, the predictive values of increased CPP and cPWV in nondialysed (ND) CKD have been less studied. [8] [9] [10] [11] [12] Furthermore, although there is plenty of evidence that detectable microvascular injury-as the other end of the spectrum of vascular dysfunction-begins at an early stage of CKD, it is not known whether this would also be predictive for CV events in CKD. Indeed, only one follow-up study 13 is available in which postocclusive reactive hyperaemia (PORH) measured by laser Doppler flowmetry (LDF) was associated with the development of CV diseases independent of Framingham and Cardiorisk cardiovascular risk scores. Furthermore, no previous study in CKD-ND considered the predictive roles of cPWV, CPP and PORH in a single cohort.
The aim of our cohort study was therefore to assess the association of micro-and macrovascular biomarkers (cPWV, CPP, PORH HA ) with traditional and nontraditional CV risk factors, and to evaluate their independent predictive value for CV events and mortality in 'mild-to-severe' CKD-ND cases.
MATERIALS AND METHODS
This was a prospective cohort study of stage 1-5 CKD-ND patients with baseline clinical, biochemical, micro-and macrovascular measurements, and with CV events and mortality as outcome during follow-up.
Patients
Initially, 108 hypertensive CKD-ND stage 1-5 individuals were enrolled with baseline clinical biochemical and vascular measurements, but only 103 individuals agreed to participate. Convenience sampling was used with consecutive inclusion of CKD patients presenting at the two tertiary care outpatient clinics that were included in our study (First Department of Internal Medicine, Semmelweis University, and St Imre University Teaching Hospital, Budapest, Hungary). They were then followed for a median of 52 (36-65) months from 2007 to 2013. Further 9 people were excluded because of missing baseline or follow-up data. Finally, 94 patients were involved and followed-up. We compared baseline characteristics of participants and nonparticipants and found no major differences between these groups.
None of the patients were hospitalized or had atrial fibrillation at the time of baseline investigations. No other specific inclusion or exclusion criteria were applied. Antihypertensive treatment was tailored according to the latest recommendations of the European Society of Hypertension for reaching target values.
14 Follow-up data were collected between April and July 2013 by telephone interviews with the patients, their general practitioners or treating physicians, and the information gathered were in all cases verified by original chart review. Follow-up was censored at the last occurrence of a documented CV event (acute coronary syndrome, heart failure requiring hospitalization, stroke or transient ischaemic attack, peripheral artery disease verified by angiography or need for an intervention) or death because of the above CV causes. Laboratory data and vascular biomarkers were not collected during follow-up.
Power analysis
Based on the observed difference of 7 mm Hg CPP in the Strong Heart Study 15 between participants with and without incident cardiovascular events, we expected a difference with similar magnitude in our population. After the enrolment of the first 25 participants, we calculated the s.d. of CPP on enrolled population (s.d. 12 mm Hg). Furthermore, based on literature data from similar populations with a median eGFR of 30-44 -ml min − 1 per 1.73 m 2 , we expected 11 cardiovascular events per 100 person-years of follow-up that translates to 44 events during the planned 4-year study. Taken together, all these information we needed to enrol 93 participants to have an 80% power to detect a 7 mm Hg difference in CPP between cases and noncases with an α of 0.05. Our observation of a difference of 8 mm Hg (47.1 ± 11.7 vs 55.2 ± 13.8 mm Hg, P = 0.004) well corresponds to the power calculations.
Macrovascular injury and blood pressure measurements
Measurements of vascular markers for a given patient (cPWV and CPP or PORH HA ) were performed in a random order after one another on the same morning at baseline. Subjects were asked to refrain from smoking on the day of the study and not to consume caffeine-containing drinks at least 4 h before the start of the measurements, but to take their regular morning medication. Tests were carried out in a temperature-controlled room (24 ± 1°C) with the subjects in supine position, after a 20 min rest period. 16 cPWV was measured by applanation tonometry (PulsePen device; DiaTecne s.r.l. Milan, Italy) 17 in accordance with the recommendations at that time 16 by capturing sequential recordings of the arterial pressure wave at the carotid and femoral arteries, and by measurement of the distance between the carotid and the femoral sampling sites. As arguments for the use of 80% of the direct carotid-femoral distance as the most accurate measurement were provided in the latest expert consensus document, our data were calculated accordingly. 18 cPWV was calculated by the PulsePen software as the ratio of the distance and the transit time of the pulse pressure wave along the aorta. Pulse wave amplitude was calibrated to brachial mean and diastolic pressures, measured immediately before each sequence of pulse wave capture at the two sites. Mean arterial pressure was calculated by the PulsePen software as diastolic pressure+0.4 pulse pressure. Recordings with a systolic or diastolic variability of consecutive waveforms above 10% or with the amplitude of the pulse wave signal being o80 mV were discarded.
All measurements were done in duplicate by JN, JE and ZsN, and their averages were used in the calculations.
CPP was measured by the same device and calculated as the difference of the central systolic blood pressure (SBP) and diastolic blood pressure (DBP) values recorded at the carotid sampling site.
All brachial blood pressure measurements throughout the study were performed by the validated oscillometric BpTRU device (VSM Meditech, Vancouver, BC, Canada) with four sequential measurements manually averaged.
Microvascular function test
For LDF measurements, blood pressure and heart rate of the subjects were determined as above. Laser Doppler instrument (Periflux 5001, Stockholm, Sweden, wavelength 780 mm) was used during the study as described previously. 19 In short, during the PORH HA test after the registration of the baseline flow for 60 s on the volar surface of the left forearm 10 cm below the elbow with a standard LDF probe, brachial arterial occlusion was applied with 40 mm Hg suprasystolic pressure by a pneumatic cuff of a sphygmomanometer for 3 min to reach the biological zero. After the release of the pressure, perfusion (measured as perfusion unit) rise high and rapidly above the pre-ischaemic PU values. The software analysed the data automatically and calculated several indices such as the initial baseline value, slope value, peak flow, percent change in perfusion from baseline to maximum values, time to reach the maximum hyperaemia, time to reach the half value after the maximum hyperaemia and the area of hyperaemia. This latter measurement (abbreviated as: PORH HA , unit: perfusion unit × s (PU × s)) seems to be the most accurate parameter to assess the hyperaemic response, as it includes three variables (speed, intensity and duration) and this was used in the analyses as representative of the microvascular function. 20, 21 In their study, Stiefel et al. 20 found a 'cutoff' PORH HA of 865 PU × s to have an 82% sensitivity and a 97% specificity to distinguish microvascular dysfunction of coronary artery disease patients from healthy controls.
According to previous measurements in our laboratory, the day-to-day variability of this system was 16-21%, which is comparable to other studies. 21 All PORH HA measurements were performed by JE and analysed by JN.
Epidemiologic and laboratory data
Baseline data on smoking habits (current), diabetes (diabetes mellitus, any type), hypertension, coronary artery disease (previous acute myocardial infarction or coronary intervention), chronic heart failure (previous diagnosis), peripheral artery disease (documented by angiography or intervention) and cerebrovascular disease (previous stroke or transient ischaemic attack) were collected by health record review. The Charlson Comorbidity Index was used for overall characterization of comorbidity of the studied population. 22, 23 Data on haemoglobin, serum calcium, phosphate, albumin, parathormon, creatinine, C-reactive protein, serum cholesterol, triglyceride, and low-density lipoprotein cholesterol were evaluated at baseline. Routine blood chemistry measurements were performed by a Hitachi (Uster, Switzerland) auto analyser. Intact parathyroid hormone 1-84 (iPTH) was determined by immune-chemiluminomtric two-site assay (CIBA-CORNING, Frenwald, Germany). Baseline eGFR was calculated using the four-variable Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 5 Circulating concentration of fibroblast growth factor-23 (FGF23) was measured using a second-generation C-terminal ELISA (Immutopics, San Clemente, CA, USA). Albuminuria was characterized by albumin-creatinine ratio measured from first morning spot urine according to KDIGO (Kidney Disease: Improving Global Outcomes) recommendations. 5 
Statistical analysis
All data analyses were performed by STATA (StataCorp, College Station, TX, USA) and Statistica version 11.0 (StatSoft Inc., Tulsa, OK, USA). Data are given as mean and s.d., unless indicated otherwise. Values are presented as median and interquartile range when data did not display a normal distribution and they were transformed logarithmically for further analyses. In the group analysis of anthropometric and clinical parameters, Student's t-test for independent samples or Mann-Whitney U-test was used as appropriate.
A total of 108 people were invited to participate, but only 103 agreed and a further 9 people were excluded because of missing baseline or follow-up data. We compared baseline characteristics of participants and Vascular biomarkers in CKD O Cseprekál et al nonparticipants and found no major differences between these groups. As the number of participants with missing data was relatively low, we used complete-case analysis. No multiple imputations were performed because of the limited sample size. In the baseline cross-sectional analyses, univariate and multivariate (stepwise, ridge) linear regressions were performed to determine the main associations of the macro-and microvascular parameters (cPWV, CPP, PORH HA ). The predictor variables considered are listed in Table 1 . The variables that showed a significant association with the given dependent variable in univariate models were considered in the final multivariate model (Table 2) .
To assess the predictive values of cPWV, CPP and PORH HA for CV events and CV mortality, multiple failure time Cox proportional hazard regression analyses were used with conditional risk set modelling. This method accommodates for the fact that one patient may have more than one outcome event. We first performed univariate analyses considering variables listed in Table 1 . Confounding was addressed in multiple linear and multivariate Cox regression models with adjustment for potential clinical predictors. Final models were selected using backward elimination to reach the most parsimonious models. (Table 3 and Supplementary Table  1 online) .
Finally, to determine the sensitivity of our data we repeated the analyses with the more usual method of censoring patients at the first occurrence of a CV event (a total of 31 events). Our main finding, that is, CPP is the only vascular marker that significantly and independently predicts outcome, has not been altered by this analysis (Supplementary Table 2 
online).
A 'P'-value with a two-sided α of 0.05 was considered statistically significant. Hazard ratios are presented with their corresponding 95% confidence interval.
Ethics CKD-ND patients in stages 1-5 who gave written, informed consent for participation were included. The study protocol was approved by the local ethical committee of the two investigation sites and it was in accordance with the principles of the Declaration of Helsinki.
RESULTS
Descriptive statistical analysis at baseline Table 1 displays baseline characteristics, concomitant diseases, traditional and nontraditional risk factors, metabolic and vascular parameters of our patients and divided into two subgroups by eGFR less than, or equal to and higher than 30 ml min − 1 per 1.73 m 2 . The causes of kidney disease were heterogeneous (number of cases in parentheses): glomerulonephritis (14), diabetic nephropathy (27) , hypertensive nephrosclerosis (14), chronic tubulointerstitial nephritis (17) , vascular cause (4), polycystic kidney disease (7), tumour (1) and unknown (10) . There were two normotensive subjects with CKD with polycystic kidney disease and glomerulonephritis. Baseline cPWV, CPP and PORH HA values were 12.5 ± 4.5 m s − 1 , 52 ± 13 mm Hg, 593 PU × s (280-1046), respectively, with no significant differences between the less and more advanced CKD groups.
At baseline there were no differences between the parameters of micro-and macrovascular damage according to the use of any antihypertensive, platelet aggregation inhibitor, erythropoietin or active vitamin D therapy. Nearly half of our population had diabetes mellitus at baseline. The diabetic group had significantly higher cPWV (14.2 ± 4.4 vs 11.3 ± 4.2, P = 0.002), lower PORH HA (421 (158-999) vs 696 (386-1139), P = 0.03), but CPP was not significantly different between the groups (54 ± 13 vs 50 ± 12, P = 0.08).
Cross-sectional analysis at baseline Baseline associations of the vascular biomarkers (that is, cPWV, CPP, lnPORH HA ) with other baseline clinical and biochemical parameters, as assessed by uni-and multivariate linear Abbreviations: ACR, albumin-creatinine ratio; β, regression coefficient; BMI, body mass index; Ca, serum calcium; Chol, cholesterol; CPP, central pulse pressure; cPWV, central pulse wave velocity; CVD, cardiovascular disease (coronary artery disease+chronic heart failure+peripheral artery disease+cerebrovascular disease); DBP, peripheral diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor-23; Hgb, haemoglobin; HR, heart rate; ln, natural-based logarithm; iP, serum inorganic phosphate; LDL, low-density lipoprotein; NA, not analysed; P, level of significance; PORH HA , post-occlusive reactive hyperaemia area; PTH, parathyroid hormone; SBP, peripheral systolic blood pressure; s.e., standard error of β; s.e.e., standard error of estimate; Tg, triglyceride. Bold and italic values represent statistically significant results.
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regressions, are displayed in Table 2 . Age, diabetes, previous CV disease and SBP were related to cPWV (R 2 = 0.3). CPP was associated with SBP and PORH HA (R 2 = 0.45). CPP was the only parameter significantly related to PORH HA (R 2 = 0.16) in the multivariate model.
Prospective data analysis During a median of 52 (36-65) months of observation time, no patients were lost to follow-up. In 31 participants, 41 CV events were recorded and used in the analyses. It represents an incidence rate of 9.8 events per 100 patient-years. The distribution of the primary events was: 14 patients died of CV causes (acute coronary syndrome 4, stroke 2, heart failure 7 and peripheral artery disease 1) and there were 27 additional CV events (acute coronary syndrome 4, stroke 6, heart failure 11 and peripheral artery disease 6). In addition, 10 patients had a second CV event, including 7 CV deaths. All 41 primary and secondary events were used as hard end points in the multiple failure time Cox regression analysis.
In univariate Cox regression analyses, all three studied vascular parameters were significantly associated with the outcome, and hazard ratios for cPWV were 1.07 (1.02-1.13), for CPP 1.04 (1.01-1.07) and for PORH HA 0.70 (0.58-0.85), respectively.
As a result of the multivariate backward Cox regression model building that included the other significant univariate predictors besides the three studied vascular parameters, only the presence of diabetes mellitus (3.06 (1.65-5.67)), lnFGF23 (1.86 (1.13-3.06)) and CPP (1.04 (1.01-1.07)) remained independent predictors of CV mortality and events (Table 3 and Supplementary Table 1 online) , whereas cPWV and lnPORH HA have lost their significant predictive value for CV events.
To determine the sensitivity of our data we repeated all these analyses with censoring patients at the first occurrence of a CV event (a total of 31 events). In this analysis, again CPP remained the only significant vascular predictor of the outcome, whereas cPWV as well as lnPORH HA lost their initial univariate significance in predicting CV outcome (supplementary Table 2 online).
DISCUSSION
The predictive role of macro-and microvascular biomarkers (cPWV, CPP, PORH HA ) on CV outcome in CKD-ND was investigated in our prospective cohort study, an analysis that has never been previously performed in a single cohort. Our main findings demonstrate that although there is an association between the markers of micro-and macrovascular injury and CV outcome, CPP seems to be the one that may best determine CV morbidity and mortality. In addition, the presence of diabetes and higher FGF23, an early marker of disturbed mineral metabolism and vascular calcification, were also found to be independent predictors of CV outcome in CKD-ND. Our population can be classified as high risk for CV diseases, as they had an event rate of 9.8 per 100 patient-years during followup. This cannot be explained solely by the presence of Framingham risk factors. 24 Indeed, the measured cPWV (12.5 ± 4.5 m s − 1 ) and CPP (52 ± 13 mm Hg) values of our patients exceeded the 'cutoff' values (PWV 410 m s − 1 and CPP 450 mm Hg, respectively) recommended by the ESH guideline and the Strong Heart Study 17,25 may in part explain this higher event rate. Our patients with an eGFR of o30 ml min − 1 per 1.73 m 2 tended to have more baseline CV diseases, such as coronary, cerebrovascular and peripheral artery disease, that likely further increased their risk of future CV events. Thus, among our patients with worsening kidney function, an increased number of comorbidities could explain the rate of events that exceeds 3 events per 100 patient-years reported by Baumann et al.
11 and the 5.13 events per 100 patient-years in Hoorn study. 26 Although in the past decade cPWV has been proven to be an independent risk factor of CV risk in the general and ESRD population, 2,3,27 only a limited number of studies had been performed with this vascular parameter in CKD-ND. In fact, only the above two prospective cohort studies investigated cPWV in a CKD-ND population. In the first study, cPWV was found to predict all-cause mortality, whereas in the latter study cPWV was related to cardiovascular events after 7.6 years of follow-up. 11, 26 Other recent studies demonstrated that decreased arterial elasticity is related to CKD progression; long-term CV outcomes have not been reported. 28, 29 There is one additional prospective cohort study by Quiroga et al.
12 who found male gender, diabetes, kidney disease progression and baseline CV disease to be predictors of all-cause mortality in their Spanish cohort. It is important to note, however, that central arterial elasticity parameters such as CPP were not examined in their study. As for the role of CPP in CKD-ND, only the cross-sectional CRIC study examined and found CPP as being superior over peripheral pulse pressure to quantify the risk of CV disease and eGFR impairment. Microvascular injury measured by LDF has not been extensively studied prospectively; Rossi et al. 30 in their cross-sectional analysis found PORH HA values to be an incremental determinant of atherosclerosis besides brachial ankle index in type I diabetes. The only prospective study performed among ESRD patients concluded that PORH HA was a determinant of coronary artery disease and all-cause mortality. 13 Our work is unique in that it is the first prospective study to investigate the combined effects of micro-and macrovascular markers, their relation to each other and their independent effects on hard CV end points in a single cohort of CKD-ND patients, never previously performed in this population.
Our cross-sectional analysis suggests that CPP might represent an early functional sign of vascular injury, to which none of the metabolic markers (for example, eGFR, anaemia, disturbed mineral metabolism) of CKD were related. We hypothesize that early stages of athero-and arteriosclerosis could lead to microstructural deterioration of central and peripheral arteries that lead to early haemodynamic dysfunction in the CKD environment. Early dysfunction of large conduit arteries (characterized by increased cPWV) may have a backward effect leading to left ventricular hypertrophy and also increase CPP. At the same time, early smallvessel dysfunction (characterized by decreased PORH) may increase wave reflections, contributing to the high pulsatile component of the aortic pressure (CPP) that directly damages target organs such as the heart, brain and kidneys. 31 Given the above physiological evidence, it seems reasonable to hypothesize that increased CPP could be an integrative marker of preclinical early target organ damage indicating both micro-and macrovascular injury. 32 Beyond CKD, traditional risk factors such as diabetes also lead to a significantly worse metabolic state, and hence accelerated athero-and arteriosclerosis. Thus, small and large arterial injuries due to these risk factors might develop simultaneously that can be extensively described by CPP as an integrative marker of CV outcome in CKD-ND. Although the presence of diabetes was expected to determine the outcome, 33 in our study, it was also independently associated with CPP, rather than cPWV, suggesting that CPP better described the clinically relevant vascular changes that occur in CKD. An explanation as for why PORH HA was not an independent predictor of outcome could be that the target organ damage characterized by increased CPP can be considered a more robust factor than a sole microvascular injury or structural central arterial stiffness marker itself. In summary, our prospective data seem to support the notion that increased CPP is indeed an early integrative marker of large and small vessel injury, with clinically relevant consequences in CKD-ND.
The plasma level of the new early biomarker of deranged mineral metabolism and vascular calcification, FGF23, rises already at initial stages of CKD and it has been shown to relate to several target organ damages leading to cardiovascular death, that is, arterial stiffness or endothelial dysfunction. Our study confirms the role of FGF23 as an independent predictor of CV death and events as summarized recently by Xiao et al. 34 in their meta-analysis.
In conclusion, the impaired pulsatile component of the central arteries characterized by increased CPP, as an integrative marker of micro-and macrovascular dysfunction, proved to be the sole, independent and robust vascular predictor of CV outcome in our CKD-ND population. CPP seems to integrate the information provided by cPWV and PORH HA . In addition, the presence of diabetes deserves special attention considering its continued predictive role for higher rate of CV events. FGF23 may also indicate increased CV risk and offer a potential future screening tool in risk stratification methods. Whether CPP can specifically be influenced by targeted vascular or metabolic therapy to alter small and large vascular function and whether all of that would have an impact on long-term CV outcome are to be seen in future diagnostic and therapeutic trials.
Limitations
There are several limitations of our study that need to be acknowledged. Although unique in its objectives, our study evaluated only a relatively small number of cases, and this makes it difficult to homogenize the cohort, smooth the variation of group composition in each CKD stages and generalize our conclusions. Furthermore, as we had small patient numbers, our confidence intervals are rather wide, and we hope that other ongoing cohort studies will support our findings on the fundamental role of CPP as an integrative marker of CV risk in this hypertensive CKD-ND population. It is important to note that beside diabetes and FGF23, only CPP was predictive for the outcome, suggesting its robustness despite the small patient numbers. Nonetheless, further studies are needed to confirm the reliability of CPP as a clinical marker of CV risk stratification. We acknowledge that this was a sample of patients of two tertiary care nephrology clinics, and therefore selection bias that may limit generalizability (that is, high baseline CV disease risk burden of our patients) cannot be ruled out. We realize that the method we used to assess microvascular reactivity with LDF and PORH HA is not entirely established. We, therefore, are awaiting the results of further studies with this method. 35 
